Go to the main menu
Skip to content
Go to bottom
REFERENCE LINKING PLATFORM OF KOREA S&T JOURNALS
> Journal Vol & Issue
Journal of Pharmaceutical Investigation
Journal Basic Information
Journal DOI :
The Korean Society of Pharmaceutical Sciences and Technology
Editor in Chief :
Volume & Issues
Volume 23, Issue 4 - Dec 1993
Volume 23, Issue 3 - Sep 1993
Volume 23, Issue 3 - Sep 1993
Volume 23, Issue 2 - Jun 1993
Volume 23, Issue 1 - Mar 1993
Selecting the target year
Conjugation of Protein and Peptide Drugs with Hydrophilic Polymers and Their Applications
Yong, Chul-Soon ; Sohn, Young-Taek ;
Journal of Pharmaceutical Investigation, volume 23, issue 4, 1993, Pages 187~206
Since the advent of recombinant DNA technology coupled with other biotechnology a variety of therapeutically effective proteins and peptides have been extensively invesitigated and many of them are now on clinical trial. They, however, suffer from some problems such as immunogenicity, antigenicity, instability and short half-life in circulation due to their proteinous natures. These drawbacks can be overcome successfully by conjugating proteins and peptides with hydrophilic polymers such as polyethylene glycol (PEG), albumin or dextran. The resulting soluble conjugates showed reduced antigenicity and immunogenicity, increased circulatory half-life, enhanced stability against proteolytic degradation. Comparing with the unmodified proteins and peptides, the therapeutic potential of conjugates is greatly enhanced. Clinical applications of these conjugates have shown promising results for the future use.
Controlled Release of Drugs from Reservoir Type Devices Coated with Porous Polyurethane Membranes
Kim, Kil-Soo ; Lee, Seung-Jin ;
Journal of Pharmaceutical Investigation, volume 23, issue 4, 1993, Pages 207~211
Reservoir type devices were designed for long-term implantable drug delivery system. The reservoir type device was prepared with the polymethacrylic acid gel coated with polyurethane membrane. Release controlling agent (RCA) were employed to control drug release from devices via generation of micropores in the membranes. The polyurethane membrane functioned as a rate controlling barrier. The drug release pattern of hydrogel demonstrated zero order kinetics. The release rate of drugs could be regulated by varying hydrophobicity/hydrophilicity and content of the RCA, as well as the thickness of the polyurethane membrane. The release of drugs from this system was governed by pore mechanism via simple diffusion and osmotic pressure.
Application of Carrageenan for Sustained Drug Release
Lee, Seung-Jin ;
Journal of Pharmaceutical Investigation, volume 23, issue 4, 1993, Pages 213~216
, an anionic polysaccharide, was employed in tablet formulations and its function as a drug release sustaining agent was investigated. Tablets composed of
and hydroxypropyl methylcellulose were fabricated by using direct compression method. Lactose and sodium alginate were utilized as controls for
. Drug release experiments performed at pHs 1.2 and 7.4 revealed that
retains pH-dependent sustained release effects due to its anionic characteristics. Also, the ionic interaction between
and drugs exerted significant affects on drug release kinetics.
was found out to be a useful additive for sustained release tablet formulations.
In Vitro and In Vivo Evaluation of the Combined Products of Antacid and Anti-ulcer Drug
Kim, Chong-Kook ; Ahn, Hye-Jin ; Jeong, Eun-Joo ; Oh, Kyung-Hee ; Lah, Woon-Lyong ;
Journal of Pharmaceutical Investigation, volume 23, issue 4, 1993, Pages 217~223
The combined products of antacid and anti-ulcer agent were prepared with antacid composed of aluminium hydroxide dried gel, magnesium hydroxide and simethicone with a ratio of 1:1:0.1 (M) and anti-ulcer agent, aceglutamide aluminium (AGA). The efficacy of antacid was evaluated in vitro with Fuchs, Johnson-Duncan and Rosset-Rice methods and in vivo using an aspiration method in rat. The addition of anti-ulcer agent did not affect the neutralizing capacity of M significantly. The combined products with the M/AGA ratios of 2.3:1 and 3.4:1 produced the maximum pH of
and the duration time of
min in vitro test. The in vivo neutralizing test in rats showed the rapid increase of gastric pH up to 3.5 within 30 min and the gastric pH of
was kept for 5 hr.
Effect of Arginine or Sodium Phosphate Dibasic on the Stability of Omeprazole in Aqueous Solution
Shim, Chang-Koo ; Han, Yong-Hae ; Woo, Jong-Soo ; Lee, Chang-Hyun ;
Journal of Pharmaceutical Investigation, volume 23, issue 4, 1993, Pages 225~229
The stability of omeprazole in the aqueous solutions containing arginine or sodium phosphate dibasic(SPD) was examined at 30, 40 and
. Arginine or anhydrous SPD was added to omeprazoie solution (
in distilled water) to yield
concentration of each. Then, the solution was kept at 30, 40 or
for 90 hrs. Aliquots of the solution were withdrawn at specified time intervals and assayed by HPLC for intact omeprazole. The remaining percentage-time curves revealed that omeprazole was degraded rapidly as funtions of time and temperature following pseudo first-order kinetics. The rate constant in the SPD solution was much higher than in the arginine solution. In other words. the degradation half-lives of omeprazole at
, for example, was 148 and 76 hr in arginine and SPD solutions respectively. The initial pH of the solution containing
of arginine or SPD was 9.7 or 8.7, respectively. Since omeprazole is more stable as the pH of its solution becomes more alkaline, the longer half-life of omeprazole in arginine solution could be explained by the more alkaline characteristics of arginine than SPD in the solution. The activation energy necessary for the degradation reaction was almost identical in both solutions, indicating similar degradation mechanisms of omeprazole in the solutions. In conclusion, omprazole was more stable in the presence of arginine than of SPD.
International Harmonization of Compendium Monographs of Pharmaceutical Excipients: Its Progress and the Matters at Issue
Sekigawa, Fujio ;
Journal of Pharmaceutical Investigation, volume 23, issue 4, 1993, Pages 231~254
These days, it is not uncommon that a same kind of drug is circulated globally. However, the qualities of excipients used in the same drug have to be sometimes different depending on the different requirements in the qualities stipulated by each country. For a supplier of pharmaceutical excipients, it is generally necessary to carry out different tests on the same kind of testing criteria depending on the country of destination. Thus, the discrepancies between compendium requirements of pharmaceutical excipients create severe problems in various area of industrial activities. The decision of the United States Pharmacopoeia, European Pharmacopoeia and Japanese Pharmacopoeia Commissions to harmonize the requirements is a unique chance for the industries to overcome these problems. On the other hand, discrepancies of general test methods and requirements in each monograph of pharmaceutical excipient between the compendia valid at present are in most cases extensive. Consequently their harmonization needs a lot of detailed work requiring strong support from the industry. Based on these circumstances, pharmaceutical excipients councils have been established first in U.S.A. and successively in Europe and in Japan to contribute to the harmorization process. We should like to review here the progress since the Orlando Conference in 1991 and comment about the matters at issue with regard to the international harmonization of pharmaceutical excipients.